GKOS changes
Pick any two versions below to diff them.
- Price
- $237.69
- Discount category
- Far above intrinsic value
- Intrinsic value source
- AI estimate
- Next earnings
- Jan 28, 2027
- Next earnings is estimate
- Yes
- Company name
- added: Glaukos
- Sector
- added: Ophthalmic medical devices and pharmaceuticals
- About
- added: Glaukos Corporation (GKOS) is based in Aliso Viejo, California. It makes products for glaucoma, corneal disorders and retinal diseases. It started Micro-Invasive Glaucoma Surgery (MIGS) with the iStent in 2012. Its iDose TR is an implant that releases travoprost inside the eye to treat glaucoma for an extended time, and Epioxa is the only FDA-approved epithelium-on treatment for keratoconus, a rare corneal disease, which it launched in March 2026. In 2025, net sales were $507.4 million. In Q3 2026, net sales were $211.0 million: U.S. glaucoma gave $118.6 million, international glaucoma $33.4 million and corneal health $59.0 million. It makes the iStent and iDose TR at its facilities in San Clemente, California, and plans a new plant in Huntsville, Alabama. The common stock trades on the NYSE in US dollars. Glaukos files 10-K and 10-Q reports.
- Thesis
- added: Investors pay more than the AI estimate for Glaukos because they expect iDose TR and Epioxa to keep sales growing fast for many years. Net sales rose 58% in Q3 2026, the gross margin was about 85%, and the company gives preliminary 2027 net sales guidance of $1 billion, against $507.4 million in 2025. For the price to hold, three things must be true. Final Medicare coverage rules for iDose TR, which five of the seven Medicare contractors proposed in 2026, must not limit its use. Commercial insurers must add coverage for Epioxa, which has had its own J-code since July 1, 2026. Operating margins must rise as sales grow, while research spending and stock-based compensation grow more slowly. The Q4 2026 report, expected in early 2027, any final coverage rules and the 2027 results are the next tests. Only several years of fast growth with higher margins can earn this price.
- Valuation
- added: The intrinsic value for Glaukos is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Glaukos with the SEC. The method is a multiple of 2027 net sales, plus cash and investments less the finance lease liability, divided by the diluted share count. The Q4 2025 release (8-K, February 17, 2026) gives 2025 net sales of $507.4 million. The Q3 2026 release (8-K, October 28, 2026) gives Q3 net sales of $211.0 million, up 58%, a gross margin of about 85%, net income of $2.0 million, non-GAAP net income of $28.5 million and 61,196 thousand diluted weighted shares for Q3. It raises 2026 net sales guidance to $775 million to $785 million and gives preliminary 2027 net sales guidance of $1 billion. Its balance sheet gives cash and cash equivalents of $162.3 million, short-term investments of $174.4 million and restricted cash of $3.1 million at September 30, 2026, or $339.8 million, no debt and a non-current finance lease liability of $66.9 million. The Form 10-Q for the quarter ended September 30, 2026 gives stock-based compensation of $65.8 million for nine months, and its cover gives 59,196,870 shares at October 26, 2026. The estimate uses the 61.2 million diluted shares. Non-GAAP results leave out stock-based compensation, so the estimate counts it through the diluted shares and the multiples, which is an assumption. The 2027 net sales and the multiples are assumptions. The low case assumes $900 million, because final Medicare coverage rules limit iDose TR and the Epioxa launch is slow, at 7 times. It gives $107.41 per share. The base case assumes the $1 billion of the guidance at 10 times. It gives $167.87 per share. The high case assumes $1,100 million, from faster growth of iDose TR and Epioxa, at 13 times. It gives $238.13 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $170.32 per share. Glaukos has FDA approvals for first-of-their-kind products, such as iDose TR and Epioxa, with patents, clinical data and a permanent J-code for Epioxa, but its growth depends on Medicare coverage decisions, and other companies develop glaucoma and keratoconus treatments. As of Nov 14, 2026.
- Risks
- added: In Q2 2026, five of the seven Medicare Administrative Contractors proposed coverage rules (LCDs) for iDose TR. Final rules that limit coverage can slow the growth of its most important product. Epioxa needs coverage from commercial insurers, because most keratoconus patients are younger than the Medicare age. A slow coverage process can delay sales. Stock-based compensation was $65.8 million in the first nine months of 2026. It increases the share count over time. Glaukos makes the iStent and iDose TR mainly in San Clemente, California, and depends on a few suppliers, some of them single-source. A disruption can stop supply. Other companies develop glaucoma implants, drug delivery products and keratoconus treatments that can compete with its products.
- Balance sheet
- added: Cash: $337M Debt: $0.0M Net cash: $337M At September 30, 2026, Glaukos had cash and cash equivalents of $162.3 million, short-term investments of $174.4 million and restricted cash of $3.1 million, or $339.8 million, and no debt. Non-current finance lease liabilities for its facilities were $66.9 million, and non-current operating lease liabilities were $35.1 million. Accrued liabilities included the $14.1 million payment to the University of California. Operating activities provided $40.9 million of cash in the first nine months of 2026. Total stockholders' equity was $717.3 million. As of Sep 30, 2026.
- Checkpoints
- added: Jan 28, 2027 (estimate): Q4 2026 results and 2027 guidance. Pending. Watch: Net sales for 2026 are in the range of $775 million to $785 million and the 2027 net sales guidance stays at $1 billion or more, and this passes; a lower 2027 guidance fails. Q1 2027 (estimate): Final Medicare coverage rules for iDose TR. Pending. Watch: The Medicare contractors issue final rules that keep iDose TR available to most patients with glaucoma, or issue no rules, and this passes; rules that limit its use to few patients fail. 2027 (estimate): 2027 net sales. Pending. Watch: Net sales for 2027 reach about $1 billion with higher operating income than in 2026, and this passes; sales below $900 million fail.
- Recent events
- added: Oct 28, 2026: Glaukos reported Q3 2026 net sales of $211.0 million, up 58%, with U.S. glaucoma sales of $118.6 million and corneal health sales of $59.0 million. Net income was $2.0 million. It raised 2026 net sales guidance to $775 million to $785 million and gave preliminary 2027 guidance of $1 billion. Oct 2, 2026: Glaukos signed agreements to develop and lease a research and manufacturing facility of about 259,000 square feet in Huntsville, Alabama, with project costs of about $42.0 million over several years. Sep 29, 2026: Glaukos agreed to pay $14.1 million to the Regents of the University of California to end all claims for payments under a 2014 patent agreement. Jul 29, 2026: Glaukos reported Q2 2026 net sales of $185.6 million, up 50%, and raised 2026 net sales guidance to $680 million to $700 million. Apr 29, 2026: Glaukos reported Q1 2026 net sales of $150.6 million, up 41%, and raised 2026 net sales guidance to $620 million to $635 million. Apr 15, 2026: CMS assigned the permanent J-code J2789 to Epioxa, effective July 1, 2026, which makes billing easier for doctors. Feb 17, 2026: Glaukos reported 2025 net sales of $507.4 million, up 32%. The Q4 2025 net loss was $133.7 million, including a non-cash impairment of $112.9 million on an acquired intangible asset, as Epioxa replaces Photrexa. Jan 13, 2026: Glaukos gave preliminary 2025 net sales of about $507 million, including iDose TR net sales of about $136 million. In January 2026, the FDA approved the re-administration of iDose TR to patients who had an earlier implant.